PGXL’s expanded lab has been accredited by the College of American Pathologists (CAP) after an exacting period of preparation and inspection. PGXL is now both CLIA and CAP certified, testament to our lab staff’s meticulous dedication.
PerMIT:Warfarin is a decision support software that provides a graphic display of historical and projected aspects of warfarin therapy. It analyzes genetic and other data to provide information physicians can apply in the dosing and monitoring of the most commonly prescribed anticoagulant.
An earlier, small study of PerMIT indicated that use of the software got patients to therapeutic stability in a shorter time than those treated without the software. This new clinical trial is designed to determine whether the software reduces the risk of adverse drug reactions in real-world therapy.
To read more about the PerMIT:Warfarin clinical trial, CLICK HERE.
Ernst & Young recognizes PGXL’s President, Dr. Roland Valdes Jr., as Entrepreneur of the Year. PGXL began as a scientific insight in Dr. Valdes’ lab at the University of Louisville — that genetic information could be used to predict the efficacy of different treatments for specific patients. PGXL has grown to more than 50 employees with a commitment to bringing the benefits of Personalized Medicine to everyone.
PGXL Technologies has formed a strategic partnership with NX PharmaGen (NXPG) to support the identification of biomarkers using their NeXosome™ microparticle enrichment technology. Exosomes and microparticles, which are found in bodily fluids, aid diagnosis and treatment of cancer, immunological disorders, preterm birth, diseases of the central nervous system and other medical conditions.
Under this partnership, NXPG and PGXL Technologies are forming the PGXL NeXosomeTM Center of Excellence, whose mission is to provide access to advanced technologies that isolate and analyze exosomes and particles in bodily fluids. This center is the first of its kind to offer access to the NeXosome enrichment platform and downstream assay development in a CLIA setting, with a mission to accelerate new discoveries into clinically useful applications.
To see the detailed press release on the agreement, CLICK HERE.
To read the technical details of the NeXosome techonlogy, CLICK HERE.
To visit PharmaGen’s website, CLICK HERE.
PGXL Technologies has been awarded $149,910 through the Kentucky Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Matching Funds program. The Kentucky SBIR-STTR funds will be used to match a federal phase NIH/NCI grant contract PGXL Technologies received in September 2013 to fund development of a platform for isolation and analysis of circulating tumor cells (CTC) in breast cancer.
To read the entire press release, please click here.
Weaver will explain her personal methodology for validating and correlating qualitative-predictive assays, particularly HER2, an important breast cancer biomarker.
Go here for information about the webinar.